Threshold Pharmaceuticals Company Profile (NASDAQ:MTEM)

About Threshold Pharmaceuticals (NASDAQ:MTEM)

Threshold Pharmaceuticals logoMolecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. It is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. Evofosfamide is designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not in healthy tissues. Tarloxotinib is under investigation in two Phase II proof-of-concept trials: one for the treatment of patients with mutant EGFR-positive, T790M-negative advanced NSCLC progressing on an EGFR TKI, and the other for patients with recurrent or metastatic squamous cell carcinomas of the head and neck. [18F]-HX4 is an investigational Positron Emission Tomography imaging agent for hypoxia to identify.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:MTEM
  • CUSIP: 88580720
  • Web: www.thresholdpharm.com
Capitalization:
  • Market Cap: $140.58 million
  • Outstanding Shares: 26,881,000
Average Prices:
  • 50 Day Moving Avg: $5.39
  • 200 Day Moving Avg: $5.70
  • 52 Week Range: $3.85 - $16.28
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.63
  • P/E Growth: 0.00
Profitability:
  • Return on Equity: -77.61%
  • Return on Assets: -61.41%
Debt:
  • Current Ratio: 8.41%
  • Quick Ratio: 8.41%
Misc:
  • Average Volume: 70,744 shs.
  • Beta: 3.31
 

Frequently Asked Questions for Threshold Pharmaceuticals (NASDAQ:MTEM)

What is Threshold Pharmaceuticals' stock symbol?

Threshold Pharmaceuticals trades on the NASDAQ under the ticker symbol "MTEM."

When did Threshold Pharmaceuticals' stock split? How did Threshold Pharmaceuticals' stock split work?

Shares of Threshold Pharmaceuticals reverse split on Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Threshold Pharmaceuticals stock prior to the reverse split would have 9 shares after the split.

How were Threshold Pharmaceuticals' earnings last quarter?

Threshold Pharmaceuticals, Inc. (NASDAQ:MTEM) released its earnings results on Monday, July, 31st. The company reported $0.22 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.77) by $0.99. The company earned $3 million during the quarter. View Threshold Pharmaceuticals' Earnings History.

Where is Threshold Pharmaceuticals' stock going? Where will Threshold Pharmaceuticals' stock price be in 2017?

3 equities research analysts have issued 12-month target prices for Threshold Pharmaceuticals' stock. Their forecasts range from $0.40 to $10.00. On average, they anticipate Threshold Pharmaceuticals' stock price to reach $5.37 in the next twelve months. View Analyst Ratings for Threshold Pharmaceuticals.

Who are some of Threshold Pharmaceuticals' key competitors?

Who are Threshold Pharmaceuticals' key executives?

Threshold Pharmaceuticals' management team includes the folowing people:

  • Harold E. Selick Ph.D., Chairman of the Board
  • Wilfred E. Jaeger M.D., Interim Chief Executive Officer, Independent Director
  • Joel A. Fernandes, Vice President - Finance, Controller
  • Mark Hopkins J.D. Ph.D., Vice President - Intellectual Property and Assistant General Counsel
  • Kristen Quigley, Vice President - Clinical Operations
  • Tillman Pearce M.D., Chief Medical Officer
  • Jeffrey W. Bird M.D. Ph.D., Independent Director
  • Bruce C. Cozadd, Independent Director
  • David R. Hoffmann, Independent Director
  • George G. C. Parker Ph.D., Independent Director

How do I buy Threshold Pharmaceuticals stock?

Shares of Threshold Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Threshold Pharmaceuticals' stock price today?

One share of Threshold Pharmaceuticals stock can currently be purchased for approximately $5.23.


MarketBeat Community Rating for Threshold Pharmaceuticals (NASDAQ MTEM)
Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  102 (Vote Outperform)
Underperform Votes:  55 (Vote Underperform)
Total Votes:  157
MarketBeat's community ratings are surveys of what our community members think about Threshold Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Threshold Pharmaceuticals (NASDAQ:MTEM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $5.37 (2.74% upside)

Analysts' Ratings History for Threshold Pharmaceuticals (NASDAQ:MTEM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/3/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy -> Buy$10.00HighView Rating Details
8/3/2017Stifel NicolausReiterated RatingHold$0.40LowView Rating Details
10/3/2016William BlairReiterated RatingOutperformN/AView Rating Details
9/30/2016S&P Equity ResearchLower Price Target$7.37 -> $5.72N/AView Rating Details
12/7/2015Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
12/7/2015Cowen and CompanyDowngradeOutperform -> Market PerformN/AView Rating Details
10/5/2015Cantor FitzgeraldReiterated RatingBuy$154.00N/AView Rating Details
9/15/2015Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
(Data available from 8/21/2015 forward)

Earnings

Earnings History for Threshold Pharmaceuticals (NASDAQ:MTEM)
Earnings by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)
Earnings History by Quarter for Threshold Pharmaceuticals (NASDAQ MTEM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2017Q2 2017($0.77)$0.22$3.00 millionViewN/AView Earnings Details
5/15/2017Q1 2017($0.88)($0.77)ViewN/AView Earnings Details
3/27/2017Q4 2016($0.77)($0.55)ViewN/AView Earnings Details
11/7/2016Q3($0.99)($0.88)ViewN/AView Earnings Details
8/1/2016Q216($1.10)($1.10)ViewN/AView Earnings Details
5/5/2016Q1($0.22)($1.21)ViewN/AView Earnings Details
3/10/2016Q4($1.21)$9.46$4.51 million$65.87 millionViewN/AView Earnings Details
11/2/2015Q315($1.54)($0.99)$3.69 million$3.70 millionViewN/AView Earnings Details
7/30/2015Q2($1.54)($1.32)$3.70 million$3.68 millionViewN/AView Earnings Details
4/30/2015($1.54)($1.87)$3.44 million$3.68 millionViewN/AView Earnings Details
3/3/2015Q414($1.43)($1.32)$4.34 million$3.68 millionViewN/AView Earnings Details
11/3/2014Q314($1.32)($1.65)$3.82 million$3.70 millionViewN/AView Earnings Details
8/1/2014($1.43)($1.32)$4.00 million$3.68 millionViewN/AView Earnings Details
5/1/2014($1.10)($1.32)$9.81 million$3.68 millionViewN/AView Earnings Details
3/6/2014Q413($1.10)($1.43)$3.58 million$3.20 millionViewN/AView Earnings Details
11/4/2013Q313($1.54)$0.22$3.15 million$3.20 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.99)($1.76)$2.80 million$2.90 millionViewN/AView Earnings Details
11/2/2012Q312($0.66)($0.66)$2.29 million$1.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Threshold Pharmaceuticals (NASDAQ:MTEM)
Current Year EPS Consensus Estimate: $-1.03 EPS
Next Year EPS Consensus Estimate: $-1.44 EPS

Dividends

Dividend History for Threshold Pharmaceuticals (NASDAQ:MTEM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Threshold Pharmaceuticals (NASDAQ:MTEM)
Insider Ownership Percentage: 12.97%
Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)
Insider Trades by Quarter for Threshold Pharmaceuticals (NASDAQ:MTEM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/1/2017Jeffrey W BirdDirectorBuy510,703$0.57$291,100.71View SEC Filing  
2/18/2015Wilfred E JaegerDirectorBuy25,000$3.75$93,750.00View SEC Filing  
10/13/2014Nipun DavarVPBuy3,000$2.99$8,970.00View SEC Filing  
10/1/2014Hill Ventures SutterMajor ShareholderSell226,657$3.77$854,496.89View SEC Filing  
10/1/2014Jeffrey W BirdDirectorSell238,520$3.77$899,220.40View SEC Filing  
6/20/2014David L AndersonMajor ShareholderSell13,988$4.01$56,091.88View SEC Filing  
1/16/2014Wilfred JaegerDirectorSell96,356$4.86$468,290.16View SEC Filing  
1/15/2014Wilfred JaegerDirectorSell424,956$4.87$2,069,535.72View SEC Filing  
1/10/2014Wilfred JaegerDirectorSell723,900$4.88$3,532,632.00View SEC Filing  
7/15/2013Wilfred E JaegerDirectorSell322,000$5.53$1,780,660.00View SEC Filing  
7/11/2013Wilfred E JaegerDirectorSell178,000$5.51$980,780.00View SEC Filing  
7/5/2013Wilfred E JaegerDirectorSell219,667$5.53$1,214,758.51View SEC Filing  
6/19/2013Wilfred E JaegerDirectorSell2,000$5.50$11,000.00View SEC Filing  
6/18/2013Wilfred E JaegerDirectorSell124,733$5.51$687,278.83View SEC Filing  
6/10/2013Wilfred E JaegerDirectorSell153,600$5.48$841,728.00View SEC Filing  
5/31/2013David L AndersonMajor ShareholderSell266,542$5.72$1,524,620.24View SEC Filing  
5/31/2013Jeffrey W BirdDirectorSell273,181$5.72$1,562,595.32View SEC Filing  
5/22/2013Tillman PearceInsiderSell20,000$5.63$112,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Threshold Pharmaceuticals (NASDAQ:MTEM)
Latest Headlines for Threshold Pharmaceuticals (NASDAQ:MTEM)
Source:

Social

Chart

Threshold Pharmaceuticals (MTEM) Chart for Monday, August, 21, 2017

This page was last updated on 8/21/2017 by MarketBeat.com Staff